Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA.
Intellectual Property is the lifeblood of the biopharmaceutical industry. The shifting legal landscape and budgetary pressures make it
Intellectual Property is the lifeblood of the biopharmaceutical industry. The shifting legal landscape and budgetary pressures make it ever more challenging to effectively protect and exploit IP assets.
Our panel of experts will discuss their views on these and other topics:
Impact of the patent reform on patent filing strategies
Subject matter eligibility under Myriad and Prometheus: US v. Rest of the World
How to properly project IP expenses and maximize ROI short and long-term
Balancing disclosure, ownership, enablement and obviousness in charting out an IP strategy
Major legal differences between biological and chemical entities
Tools and resources available to for patent analyses and IP management
Steven A. Kriston, JD, Regional Consultant, Innovation and Asset Management, IP Solutions, Thomson Reuters
Robert Silverman, JD, PhD, Sr. Vice President and General Counsel, Concert Pharmaceuticals
Jennifer Zarutskie Sieczkiewicz, JD, PhD, Director of IP Strategy and Operations, Biogen Idec
Konstantin Linnik, JD, PhD, Partner, Intellectual Property Department, Nutter McClennen & Fish LLP